CF drug combo trial halted early – did it work?
NCT ID NCT02323100
First seen Apr 25, 2026 · Last updated May 14, 2026 · Updated 2 times
Summary
This early-stage trial tested whether adding glycerol phenylbutyrate (Ravicti) to standard pancreatic enzyme therapy could improve chloride transport in the nasal cells of adults with cystic fibrosis. Only 16 people enrolled, and the study was terminated before completion. The goal was to see if the combination could help correct the underlying CF defect, but results are limited due to early stopping.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Johns Hopkins University School of Medicine
Baltimore, Maryland, 21205, United States
-
National Jewish Health
Denver, Colorado, 80206, United States
Conditions
Explore the condition pages connected to this study.